Research map: The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer

Back to the article

Papers in this map

  1. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer · Fátima Cardoso · 2016 · 2100 citations · Cited by this paper
  2. Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer · 2026 · Related
  3. Regression modelling strategies for improved prognostic prediction · Frank E. Harrell · 1984 · 1849 citations · Cited by this paper
  4. Global Burdens and Trends of Breast Cancer Attributable to Dietary and Metabolic Risks: A 30-Year Analysis With Projections to 2050, Including Males and Females · 2026 · Related
  5. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer · Joseph A. Sparano · 2015 · 1453 citations · Cited by this paper
  6. Effect of Treatment Sequencing in Older Adults With Early Breast Cancer. Insights From a Retrospective Single-Institution Cohort · 2026 · Related
  7. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial · R. Jakesz · 2005 · 881 citations · Cited by this paper
  8. Patients With Luminal Breast Carcinoma: The State of the Field in Proteomic and Proteogenomic Molecular Subtyping · 2026 · Related
  9. Reporting Recommendations for Tumor Marker Prognostic Studies · Lisa M. McShane · 2005 · 784 citations · Cited by this paper
  10. Methodological Concerns Regarding the Assessment of Breast Cancer Risk Following Gender-Affirming Care · 2026 · Related
  11. A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors · Martin Filipits · 2011 · 739 citations · Cited by this paper
  12. Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer · 2026 · Related
  13. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone · Michael Gnant · 2013 · 409 citations · Cited by this paper
  14. Association of Regional Anesthesia With Reduced Post-discharge Opioid Prescriptions Following Immediate Autologous Breast Reconstruction: An ACS-NSQIP Analysis · 2026 · Related
  15. The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer · Martin Filipits · 2014 · 220 citations · Cited by this paper
  16. Evaluation of Absorbable Hemostatic Powder on Post-operative Outcomes in Patients Undergoing Mastectomy · 2026 · Related
  17. Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group · Peter Christian Dubsky · 2012 · 100 citations · Cited by this paper
  18. Feasibility of Same Day Mastectomy Discharge in a Safety Net Hospital in Memphis, TN · 2026 · Related
  19. Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only · Martin Filipits · 2019 · 78 citations · Cited by this paper
  20. CTSG suppresses breast cancer progression by inhibiting the EGFR/ERK signaling pathway and enhancing CD8⁺ T cell activation · 2026 · Related
  21. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform · Natalie Wu · 2018 · 56 citations · Cited by this paper
  22. Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer · Ivana Šestak · 2020 · 38 citations · Cited by this paper
  23. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6 · Martin Filipits · 2021 · 25 citations · Cited by this paper
  24. Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study · Richard Buus · 2019 · 18 citations · Cited by this paper
  25. Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node‐negative breast cancer patients · Fiona T. Lanigan · 2015 · 17 citations · Cited by this paper
  26. Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer · Zsuzsanna Bagó-Horváth · 2011 · 16 citations · Cited by this paper
  27. Master Transcriptional Regulators in Cancer: Discovery via Reverse Engineering Approaches and Subsequent Validation · Bruce Moran · 2017 · 16 citations · Cited by this paper
  28. Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer · Tony Loughman · 2018 · 4 citations · Cited by this paper
  29. Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR-positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland. · Darran P. O’Connor · 2019 · 3 citations · Cited by this paper
  30. The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8 · Martin Filipits · 2021 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)